145 related articles for article (PubMed ID: 24175292)
1. Potential impact of a free online HIV treatment response prediction system for reducing virological failures and drug costs after antiretroviral therapy failure in a resource-limited setting.
Revell AD; Alvarez-Uria G; Wang D; Pozniak A; Montaner JS; Lane HC; Larder BA
Biomed Res Int; 2013; 2013():579741. PubMed ID: 24175292
[TBL] [Abstract][Full Text] [Related]
2. Computational models can predict response to HIV therapy without a genotype and may reduce treatment failure in different resource-limited settings.
Revell AD; Wang D; Wood R; Morrow C; Tempelman H; Hamers RL; Alvarez-Uria G; Streinu-Cercel A; Ene L; Wensing AM; DeWolf F; Nelson M; Montaner JS; Lane HC; Larder BA;
J Antimicrob Chemother; 2013 Jun; 68(6):1406-14. PubMed ID: 23485767
[TBL] [Abstract][Full Text] [Related]
3. An update to the HIV-TRePS system: the development and evaluation of new global and local computational models to predict HIV treatment outcomes, with or without a genotype.
Revell AD; Wang D; Wood R; Morrow C; Tempelman H; Hamers RL; Reiss P; van Sighem AI; Nelson M; Montaner JS; Lane HC; Larder BA;
J Antimicrob Chemother; 2016 Oct; 71(10):2928-37. PubMed ID: 27330070
[TBL] [Abstract][Full Text] [Related]
4. An update to the HIV-TRePS system: the development of new computational models that do not require a genotype to predict HIV treatment outcomes.
Revell AD; Wang D; Wood R; Morrow C; Tempelman H; Hamers R; Alvarez-Uria G; Streinu-Cercel A; Ene L; Wensing A; Reiss P; van Sighem AI; Nelson M; Emery S; Montaner JS; Lane HC; Larder BA;
J Antimicrob Chemother; 2014 Apr; 69(4):1104-10. PubMed ID: 24275116
[TBL] [Abstract][Full Text] [Related]
5. 2018 update to the HIV-TRePS system: the development of new computational models to predict HIV treatment outcomes, with or without a genotype, with enhanced usability for low-income settings.
Revell AD; Wang D; Perez-Elias MJ; Wood R; Cogill D; Tempelman H; Hamers RL; Reiss P; van Sighem AI; Rehm CA; Pozniak A; Montaner JSG; Lane HC; Larder BA;
J Antimicrob Chemother; 2018 Aug; 73(8):2186-2196. PubMed ID: 29889249
[TBL] [Abstract][Full Text] [Related]
6. The Evolving Landscape of HIV Drug Resistance Diagnostics for Expanding Testing in Resource-Limited Settings.
Inzaule SC; Hamers RL; Paredes R; Yang C; Schuurman R; Rinke de Wit TF
AIDS Rev; 2017; 19(4):219-230. PubMed ID: 28182618
[TBL] [Abstract][Full Text] [Related]
7. A longitudinal analysis of healthcare costs after treatment optimization following genotypic antiretroviral resistance testing: does resistance testing pay off?
Simcock M; Sendi P; Ledergerber B; Keller T; Schüpbach J; Battegay M; Günthard HF;
Antivir Ther; 2006; 11(3):305-14. PubMed ID: 16759046
[TBL] [Abstract][Full Text] [Related]
8. A comparison of computational models with and without genotyping for prediction of response to second-line HIV therapy.
Revell AD; Boyd MA; Wang D; Emery S; Gazzard B; Reiss P; van Sighem AI; Montaner JS; Lane HC; Larder BA
HIV Med; 2014 Aug; 15(7):442-8. PubMed ID: 24735474
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of genotypic antiretroviral resistance testing in HIV-infected patients with treatment failure.
Sendi P; Günthard HF; Simcock M; Ledergerber B; Schüpbach J; Battegay M;
PLoS One; 2007 Jan; 2(1):e173. PubMed ID: 17245449
[TBL] [Abstract][Full Text] [Related]
10. 2021 update to HIV-TRePS: a highly flexible and accurate system for the prediction of treatment response from incomplete baseline information in different healthcare settings.
Revell AD; Wang D; Perez-Elias MJ; Wood R; Cogill D; Tempelman H; Hamers RL; Reiss P; van Sighem A; Rehm CA; Agan B; Alvarez-Uria G; Montaner JSG; Lane HC; Larder BA;
J Antimicrob Chemother; 2021 Jun; 76(7):1898-1906. PubMed ID: 33792714
[TBL] [Abstract][Full Text] [Related]
11. Drug resistance testing through remote genotyping and predicted treatment options in human immunodeficiency virus type 1 infected Tanzanian subjects failing first or second line antiretroviral therapy.
Svärd J; Mugusi S; Mloka D; Neogi U; Meini G; Mugusi F; Incardona F; Zazzi M; Sönnerborg A
PLoS One; 2017; 12(6):e0178942. PubMed ID: 28582463
[TBL] [Abstract][Full Text] [Related]
12. The clinical and economic impact of genotype testing at first-line antiretroviral therapy failure for HIV-infected patients in South Africa.
Levison JH; Wood R; Scott CA; Ciaranello AL; Martinson NA; Rusu C; Losina E; Freedberg KA; Walensky RP
Clin Infect Dis; 2013 Feb; 56(4):587-97. PubMed ID: 23087386
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness of antiretroviral regimens containing abacavir with tenofovir in treatment-experienced patients: predictors of virological response and drug resistance evolution in a multi-cohort study.
Di Giambenedetto S; Torti C; Prosperi M; Manca N; Lapadula G; Paraninfo G; Ladisa N; Zazzi M; Trezzi M; Cicconi P; Corsi P; Nasta P; Cauda R; De Luca A; ; ;
Infection; 2009 Oct; 37(5):438-44. PubMed ID: 19669091
[TBL] [Abstract][Full Text] [Related]
14. Economic evaluation of drug resistance genotyping for the adaptation of treatment in HIV-infected patients in the VIRADAPT study.
Chaix C; Grenier-Sennelier C; Clevenbergh P; Durant J; Schapiro JM; Dellamonica P; Durand-Zaleski I
J Acquir Immune Defic Syndr; 2000 Jul; 24(3):227-31. PubMed ID: 10969346
[TBL] [Abstract][Full Text] [Related]
15. Cost-efficacy comparison among three antiretroviral regimens in HIV-1 infected, treatment-experienced patients.
Ruof J; Dusek A; DeSpirito M; Demasi RA
Clin Drug Investig; 2007; 27(7):469-79. PubMed ID: 17563127
[TBL] [Abstract][Full Text] [Related]
16. The cost effectiveness of combination antiretroviral therapy for HIV disease.
Freedberg KA; Losina E; Weinstein MC; Paltiel AD; Cohen CJ; Seage GR; Craven DE; Zhang H; Kimmel AD; Goldie SJ
N Engl J Med; 2001 Mar; 344(11):824-31. PubMed ID: 11248160
[TBL] [Abstract][Full Text] [Related]
17. Expanding antiretroviral options in resource-limited settings--a cost-effectiveness analysis.
Bendavid E; Wood R; Katzenstein DA; Bayoumi AM; Owens DK
J Acquir Immune Defic Syndr; 2009 Sep; 52(1):106-13. PubMed ID: 19448557
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness analysis of emtricitabine/tenofovir versus lamivudine/zidovudine, in combination with efavirenz, in antiretroviral-naive, HIV-1-infected patients.
Sánchez-de la Rosa R; Herrera L; Moreno S
Clin Ther; 2008 Feb; 30(2):372-81. PubMed ID: 18343275
[TBL] [Abstract][Full Text] [Related]
19. Cost effectiveness analysis of routine use of genotypic antiretroviral resistance testing after failure of antiretroviral treatment for HIV.
Corzillius M; Mühlberger N; Sroczynski G; Jaeger H; Wasem J; Siebert U
Antivir Ther; 2004 Feb; 9(1):27-36. PubMed ID: 15040534
[TBL] [Abstract][Full Text] [Related]
20. Cost of Human Immunodeficiency Virus (HIV) and Determinants of Healthcare Costs in HIV-Infected Treatment-Naive Patients Initiated on Antiretroviral Therapy in Germany: Experiences of the PROPHET Study.
Valbert F; Wolf E; Schewe K; Klauke S; Hanhoff N; Hoffmann C; Preis S; Pahmeier K; Wasem J; Neumann A
Value Health; 2020 Oct; 23(10):1324-1331. PubMed ID: 33032776
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
